The awful lesson of Thalidomide
The New York Times has taken a look at the awful history of Thalidomide, the drug which caused thousands of children around the world to be born with deformed and shortened limbs. It is deeply disturbing.
The New York Times has taken a look at the awful history of Thalidomide, the drug which caused thousands of children around the world to be born with deformed and shortened limbs. It is deeply disturbing. In the 1950s the German pharmaceutical company Chemie Grünenthal marketed it as a safe sleeping pill and as a remedy for morning sickness. Nowadays it is being used as to treat leprosy, especially in Brazil. Despite all the warnings, children are still being born there with severe defects. (Click here to see video.)
- Queensland legalises ‘assisted dying’ - September 19, 2021
- Is abortion a global public health emergency? - April 11, 2021
- Dutch doctors cleared to euthanise dementia patients who have advance directives - November 22, 2020
Mortality rates for American kids are rising for the first time in 50 years
US President Joe Biden is so concerned about the future of American children that he inserted a mandate for affordable...
Will Pope Francis be composted?
Will Pope Francis be composted instead of buried in St Peter’s Basilica in Rome with his predecessors? It’s unlikely. But...
The virtues and the vices of the outrageous
A Norwegian bioethicist, Anna Smajdor, recently set out a case for “Whole Body Gestational Donation” – using the wombs of...
More than 200 people have been treated with experimental CRISPR therapies
Scientists believe that CRISPR gene editing technologies will transform medicine. But how many people have been treated so far? According...
Asia-Pacific IVF market could reach US$46 billion by 2031
According to a market survey by Allied Market Research, IVF is booming in the Asia-Pacific region. The market size was...
Third global summit on human genome editing: Moving on after the He experiment
The much anticipated Third International Summit on Human Genome Editing was held in London earlier this month to explore the...